Atea Pharmaceuticals, Inc. - common stock (NQ:AVIR)

Atea Pharmaceuticals to Present at the Morgan Stanley 24th Annual Global Healthcare Conference

September 08, 2026

Performance

52-Week Range 30.9% below 52-week high

4.460

2.8752W Low 6.4552W High

1 Week 0.9% below 1-week high

3.941W Low 4.501W High

Atea Pharmaceuticals, Inc. - common stock (AVIR) traded between $2.87 and $6.45 over the past 52 weeks and last traded at $4.46, 30.9% below its 52-week high. Over the past week it ranged between $3.94 and $4.50.

Past 12 Months

+3.5%

-13.1%

-6.1%

-21.1%

+28.2%

+38.9%

1W +$0.15

1M -$0.67

3M -$0.29

6M -$1.19

YTD +$0.98

1Y +$1.25

AVIR was +38.9% over the past year, -21.1% over six months, +28.2% year to date, +3.5% in the last week.

12 Months vs Market

AVIR

+38.9%

DIA

+13.2%

SPY

+13.6%

QQQ

+11.7%

IWM

+17.8%

Over the past 12 months AVIR returned +38.9% versus DIA (Dow) +13.2%, SPY (S&P 500) +13.6%, QQQ (Nasdaq 100) +11.7% and IWM (Russell 2000) +17.8%.

Volume & Liquidity

324.2K

305.4K

281.5K

322.8K

YTD

385.6K

388.5K

AVIR's 3-month average daily volume is 281.5K.

More News

Atea (AVIR) Q2 2026 Earnings Call Transcript ↗

August 19, 2026

Atea Pharmaceuticals (NASDAQ:AVIR) Q1 Loss Narrows as HCV and HEV Pipeline Catalysts Loom ↗

May 12, 2026

Via Chartmill

Atea Pharmaceuticals (NASDAQ:AVIR) Reports Q4 2025 Results as HCV and HEV Pipeline Advance ↗

March 05, 2026

Via Chartmill

Atea Pharmaceuticals Q2 Earnings Call Highlights ↗

August 12, 2026

Via MarketBeat

Atea Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update

August 12, 2026

Atea Pharmaceuticals to Host Second Quarter 2026 Financial Results and Business Update Conference Call on August 12, 2026

August 05, 2026

Atea Pharmaceuticals Meets Both Its Primary and Secondary Endpoints in the Phase 3 C-BEYOND North America Trial Evaluating Bemnifosbuvir/Ruzasvir for Hepatitis C Virus

July 28, 2026

Atea Pharmaceuticals Initiates First-in-Human Phase 1 Clinical Trial of AT-587 for the Treatment of Hepatitis E Virus

July 14, 2026

Atea Pharmaceuticals Completes Patient Enrollment in Phase 3 C-FORWARD Trial Evaluating Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus

June 25, 2026

Atea Pharmaceuticals Presents New Drug-Drug Interaction Results Supporting Potential Best-in-Class Profile of the Regimen of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at EASL Congress 2026

May 27, 2026

Atea Pharmaceuticals to Present Three Abstracts at EASL 2026 Congress Highlighting Progress Across Viral Hepatitis Pipeline

May 13, 2026

Atea Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update

Atea Pharmaceuticals Q1 Earnings Call Highlights ↗

May 12, 2026

Via MarketBeat

May 12, 2026

Atea Pharmaceuticals to Host First Quarter 2026 Financial Results and Business Update Conference Call on May 12, 2026

May 05, 2026

Atea Pharma (AVIR) Earnings Call Transcript ↗

March 05, 2026

Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

March 05, 2026

Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2025 Financial Results and Business Update Conference Call on March 5, 2026

February 26, 2026

Atea Pharmaceuticals Presents Preclinical Results Supporting First-in-Class Potential of AT-587 for Treatment of Hepatitis E Virus at CROI 2026

February 24, 2026

CarMax Stock Down 47% This Past Year, But One Fund Is Betting $6 Million on a Turnaround ↗

February 03, 2026

Alumis Stock Has Rallied 250% This Past Year. One Fund Sold Its $5 Million Stake Last Quarter. ↗

February 03, 2026

Atea Pharmaceuticals to Highlight 2026 Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference

January 08, 2026

Atea Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference

January 06, 2026